Brief: Actuate Therapeutics Announces Interim Phase 2 Data Of Elraglusib
17/12/2024 14:05
Dec 17 (Reuters) - Actuate Therapeutics Inc ACTU.O :
* ACTUATE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2
DATA OF
ELRAGLUSIB IN FIRST LINE TREATMENT OF METASTATIC PANCREATIC
CANCER
* ACTUATE THERAPEUTICS INC - ELRAGLUSIB IN COMBINATION WITH
GNP
SHOWS FAVORABLE RISK-BENEFIT PROFILE
* ACTUATE THERAPEUTICS INC - TRIAL MET PRIMARY SAFETY
ENDPOINT,
FAVORABLE RISK-BENEFIT PROFILE
Source text: ID:nGNX81F1jl
Further company coverage: ACTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsHealth Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
Brief: Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing